Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2015

View Archived Issues

Shire reports pipeline highlights of fourth quarter 2014

Zydus completes phase I studies of ZYAN-1

Impaired mTORC1 activity linked to phenotypic changes associated with Huntington's disease

Saniona regains rights to GABA-alpha5 program

Otsuka Pharmaceutical recaps highlights of third quarter of fiscal 2014

VistaGen and NIH sign agreement for phase II AV-101 trial in major depressive disorder

FDA grants fast track designation to intranasal naloxone treatment

FDA gives orphan drug status to entrectinib for colorectal cancer

Nanjing Sanhome Pharmaceutical patents ABL inhibitors

Phase II trial of MRX-6 in pediatric atopic dermatitis does not reach primary endpoint

Alethia Biotherapeutics submits clinical trial application for AB-16B5

PBI-4050 granted U.S. orphan drug status for IPF

VBL Therapeutics reports data from VB-201 trials in psoriasis and ulcerative colitis

Roche develops neurogenesis-stimulating naphthyridines

Zenith Epigenetics reports novel bromodomain inhibitors

Nattokinase shows efficacy for ischemic brain damage

Novartis patent divulges PI3Kdelta/gamma inhibitors

Intrexon to acquire recombinant bacterial therapeutics developer ActoGeniX

Takeda Pharmaceutical patents new PDE2A inhibitors

ADAMTS13, a potential biomarker of response to thrombolysis in acute stroke

Alzheimer's Research U.K. funds three drug discovery institutes

Sprout Pharmaceuticals resubmits NDA for flibanserin in HSDD

Elite Pharmaceuticals plans phase III trial of abuse-deterrent opioid

SB-623 cell therapy shows encouraging results for chronic stroke

Pluristem Therapeutics reports results for PLX-R18 in animal model of ARS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...